key: cord-1039017-ed5budov
authors: Morales, Leon; Gambhir, Yuva; Bennett, Jean; Stedman, Hansell H.
title: Broader Implications of Progressive Liver Dysfunction and Lethal Sepsis in Two Boys Following Systemic Administration of High-dose AAV
date: 2020-07-16
journal: Mol Ther
DOI: 10.1016/j.ymthe.2020.07.009
sha: 3500a420356514a5ce105dcd0c69000515970fe7
doc_id: 1039017
cord_uid: ed5budov

nan

By virtue of their transformational power, the technologies at the core of the gene therapy community have brought widespread public attention to the unique burden of previously neglected orphan diseases. On June 23, a report from Audentes Therapeutics of the tragic death of two patients with X-linked myotubular myopathy (XLMTM) (https://www.joshuafrase.org/get-involved/recensus-study.php) brought into ever sharper focus an added dimension of this burden. XLMTM is recognized for its devastating prognosis in terms of standardized metrics including disability-adjusted life years and healthy life expectancy. Highly publicized reports of the earliest results of Audentes' ASPIRO gene therapy trial revealed a spectacular therapeutic response. Both the specifics and the broader context of the unexpected adverse events illustrate why for patients and their families the stakes have never been higher as the limitations of initially promising therapies become fully known only through advanced phase clinical trials. Transparency to enable a better understanding of the clinical pathology will be essential to inform the risk-benefit calculus for XLMTM patients contemplated enrollment in future trials, but also for the broader community to enable rationale design of improved gene therapy vectors.

The specifics of Audentes' letter addressed to the "XLMTM Patient Community" can be briefly summarized: two of the three older patients in the AT132 (AAV8-MTM1) high dose cohort (3x10 14 vg/kg) died following clinically similar courses, approximately 4-6 weeks postadministration, in the setting of progressive liver dysfunction and sepsis. The observation of serious adverse events (SAEs) of hepatobiliary disease included all three of the older patients in this dose cohort. Four of six patients previously treated at 1x10 14 vg/kg had no liver SAEs despite previous histories of hepatobiliary disease associated with XLMTM.

Understanding of the broader context of these SAEs is critical to define the pathway forward. It begins with the devastating disease first described by Spiro, Shy, and Gonatas in 1966, and christened myotubular myopathy on the basis of the histological appearance of the centronuclear myocytes resembling fetal myotubes. The protein product of the X-linked gene (MTM1), myotubularin, is a ubiquitously expressed PI(3)P phosphatase. 1, 2 The resulting lipid second messenger is involved in endosome trafficking, autophagy, desmin filament architecture, mitochondrial dynamics, muscle excitation-contraction coupling, and regulation of the ubiquitin-proteasome pathway. 3, 4 The spectrum of XLMTM clinical phenotypes was first broadly characterized 20 years ago with an estimated 50% mortality by 18 months of age. Recent refinement 5 revealed improvement in survival to a median age of 12 years through long-term mechanical respiratory support, but re-affirmed the extraordinary burden of disease with 87% of patients non-ambulant with heavy dependence on gastrostomy tube feeding.

As with the majority of myopathies and muscular dystrophies, there remain major gaps in our understanding of XLMTM pathogenesis. Nonetheless, establishment of a canine model from a naturally occurring missense mutation 6 provided an opportunity to explore investigational therapies agnostic to the exact function of the gene product. 7, 8 Unlike dystrophin, the 71.6 kd molecular weight of myotubularin puts its 2 kb cDNA well within the cloning capacity of AAV vectors, facilitating a remarkably rapid progression of critical translational steps. The efficacy of systemic gene delivery using an AAV8 vector with the human desmin promoter driving MTM1 expression was unprecedented for a large animal disease model, with a dramatic survival advantage noted in the earliest treatment cohort. Audentes Therapeutics moved rapidly to license and commercialize the investigational therapy based largely on patent US20140249211A1, selecting doses of 1x and 3x10 14 vg/kg for systemic delivery. Publicly available documents describe the company's rationale for shifting from the baculovirus/sf9 insect cell platform used for the pivotal preclinical studies to the suspension 293 cell platform. In 2019 the company reported that "treated patients across both dose cohorts show significant reductions in ventilator dependence and the progressive attainment of developmental motor milestones" in support of previously announced plans to work "with the FDA to advance AT132 to registration as quickly as possible". Audentes announced plans for a large vector manufacturing facility in Sanford North Carolina. As of June 30, multiple news outlets report that in response to the deaths cited above, the FDA had placed a clinical hold on further development of AT132, with Audentes postponing plans to submit a Biologics License Application.

This tragic turn of events graphically illustrates the scope and magnitude of challenges in biologics development and regulation, and above all, the emotional turmoil faced by the most critical community of stakeholders. AT132's rapid development to this point was driven in large part by the level of organization and commitment of the XLMTM community and the Joshua Frase Foundation, as illustrated by the identification of the canine model. What can be learned from these devastating SAEs to rapidly yet rationally mitigate the risk to XLMTM patients for whom the durability, efficacy, and safety of future treatment may hinge on seemingly minor adjustments in vector design?

In view of the reported timing, tissue-specificity, and dose-dependency, plausible mechanisms for lethal toxicity must emphasize hepatotoxicity from the vector capsid or transgene product, perhaps driven by adaptive and/or innate immune responses. Although the investigator brochure is not in the public domain, the 3x10 14 vg/kg dose of AAV vector is the highest ever used in humans. This suggests that the authorized interval of close monitoring between patients injected within this cohort would have been at least 4 weeks, providing circumstantial evidence against an innate immune response as the primary etiology. Interpretation is further complicated by an aspect of the disease that is poorly understood, not seen in animal models and rarely reported in other human myopathies: a significant proportion of XLMTM patients have underlying liver disease. In its extreme form, peliosis hepatis, there is risk of exsanguinating hemorrhage. Prior reports emphasize the morbidity/mortality of opposing outcomes: forensic examination of the liver at autopsy to rule out death by suspected caregiver abuse 9 or survival by virtue of emergency, living-related donor liver transplantation. 10 The ASPIRO trial was designed to mitigate this risk by excluding subjects with "clinically significant underlying liver disease" (NCT03199469), yet four of the first six patients enrolled were cited in the Audentes letter as having previous histories of hepatobiliary disease.

As with other AAV vectors under clinical investigation at high systemic dose for neuromuscular disease (AAV9 and Rh74), the AAV8 capsid serotype was initially identified and commercially developed on the basis of its high tropism for the liver. It is notable that in a follow up study in the XLMTM (MTM1-N155K) canine model, theoretical concern was expressed about "potential off-target effects, such as in the liver," which might be addressed by selective tissue de-targeting with other capsids and/or promoters. 8 Furthermore, it was noted by these authors that the dose-response study was limited to 0.3x10 14 , 2.0x10 14 , and 5x10 14 vg/kg, with the latter two doses showing dose-dependent increases in vg content in most tissues but indistinguishable in terms of gait speed at 17 weeks, and no data for 1.0x10. However, there are no published reports of hepatotoxicity in the murine or canine XLMTM models following AAV8.Des.MTM1 treatment.

The mutational spectrum in human XLMTM includes deletions, frameshifts, and early nonsense codons. Thus, as with the various canine models for Duchenne muscular dystrophy DMD, the possibility remains that central immunological tolerance to the full length product of the canine MTM1 p.N155K allele might mask adaptive immunotoxicity. 11 In canine XLMTM, AAV8 had higher tropism for the left ventricle and liver than any other tissues including skeletal muscle, 8 and in the ASPIRO clinical trial three of the first ten patients had laboratory findings indicative of myocarditis or cholestasis. 12 Interestingly, myotubularin is the first identified member of a family of fourteen paralogs or "MTMR"s. Although MTM1 is ubiquitously expressed, disruption of excitation-contraction coupling is unique to skeletal muscle, suggesting that cardiac myocytes are unaffected because they co-express additional isoforms, e.g. MTMR14 which is also involved in the trophic response to hemodynamic load. Perhaps substitution of an MTMR for MTM1 would eliminate the risk of adaptive immunotoxicity, as with utrophin for DMD in the setting of deletional/frameshift loss of dystrophin. 11 The most serious of unanticipated adverse events in gene/cell therapy clinical trials can take years to decipher, integrating information from forensic pathology and hypothesis-driven, mechanistic dissection. 13, 14 Meanwhile, an added dimension of the burden for the XLMTM community is acknowledging the potential impact of their advocacy for alternative paths forward in the face of grave uncertainty, e.g. vector modification requiring new preclinical studies versus continued investigation of AAV8.Des.MTM1 at the 1x10 14 vg/kg dose. A major factor in the risk tolerance of research subjects is the individualized perception of time, as can be framed by survey instruments within the stakeholder community to weigh the high morbidity and lethal natural history of the disease against informed estimates of the risks of accessing the only potentially life-improving/saving, investigational therapy on the immediate horizon. As soon as possible, the findings of clinical toxicology must be made public to accelerate the development of novel vectors with the expectation of a substantially improved therapeutic index. Meanwhile, the inclusion/exclusion criteria, informed consent, and data monitoring protocols must be overhauled and continuously updated to integrate the implications of new findings, with revised estimates of risks and potential benefits to XLMTM research subjects at specific vector doses.

One change that the entire field of gene therapy would benefit from is increased disclosure in cases of fatal SAEs as in the current study. Companies, clinicians and the FDA would all be able to apply the hard-won lessons learned from these negative studies to improve the design and testing of future constructs. We appreciate the sensitivity of disclosing detailed results of company sponsored studies, but mechanisms to protect confidentiality while disseminating life-critical information can be developed, as will also be critical on a global scale in the months ahead with the rapid evaluation of candidate COVID-19 vaccines against the risk of enhanced respiratory disease. 15 LM is a PhD thesis student working under the joint mentorship of Drs. Bennett and Stedman, and has been evaluated for participation in a clinical trial for Fascioscapularhumeral muscular dystrophy. YG is an undergraduate at the University of Pennsylvania, and is currently enrolled in a clinical trail for an experimental therapy for Duchenne muscular dystrophy. JB has received grants from the Foundation Fighting Blindness, the National Institutes of Health, and Spark Therapeutics; non-financial support from the Center for Advanced Retinal and Ocular Therapeutics, University of Pennsylvania, and the FM Kirby Foundation; has a provisional patent pending and a US patent licensed to Spark Therapeutics for which she has waived financial interest. HHS has received grants from the Muscular Dystrophy Association, National Institutes of Health, and is an inventor on provisional and issued patents licensed to StrongHolt Therapeutics and 4MVac, for which he has served as a co-founder.

A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast

Myotubularin, a protein tyrosine phosphatase mutated in myotubular myopathy, dephosphorylates the lipid second messenger, phosphatidylinositol 3-phosphate

T-tubule disorganization and defective excitation-contraction coupling in muscle fibers lacking myotubularin lipid phosphatase

Myotubularin controls desmin intermediate filament architecture and mitochondrial dynamics in human and mouse skeletal muscle

X-linked myotubular myopathy: A prospective international natural history study

MTM1 mutation associated with X-linked myotubular myopathy in Labrador Retrievers

Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy

Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs

An autopsy case of peliosis hepatis with X-linked myotubular myopathy

Livingdonor liver transplantation for liver hemorrhaging due to peliosis hepatis in X-linked myotubular myopathy: Two cases and a literature review

Nonimmunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models

High dose systemic gene therapy: emerging trends on safety and efficacy

Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency

Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells

Development and Licensure of Vaccines to Prevent COVID-19, Guidance for Industry